# EDGAR Filing Document

**Accession Number:** 0001497253
**File Stem:** 0000950170-25-108447
**Filing Date:** 2025-8
**Character Count:** 21720
**Document Hash:** abcdc114ecacb8d4a4b71f784bba43b2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-108447.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0000950170-25-108447

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250814

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VivoSim Labs, INC.
- **CENTRAL INDEX KEY:** 0001497253
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 271488943
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35996
- **FILM NUMBER:** 251214481

**BUSINESS ADDRESS:**
- **STREET 1:** 11555 SORRENTO VALLEY ROAD
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-224-1000

**MAIL ADDRESS:**
- **STREET 1:** 11555 SORRENTO VALLEY ROAD
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ORGANOVO HOLDINGS, INC.
- **DATE OF NAME CHANGE:** 20120104

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** REAL ESTATE RESTORATION & RENTAL, INC.
- **DATE OF NAME CHANGE:** 20100722

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## **FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** August 14, 2025<br>

------

VivoSim Labs, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-35996 | 27-1488943 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 11555 Sorrento Valley Rd<br>Suite 100 |  |  |
| San Diego**,** California |  | 92121 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (858) 224-1000<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value | VIVS | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## **Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** 
On August 7, 2025, the Board of Directors (the "Board") of VivoSim Labs, Inc. (the "Company") appointed Tony Lialin, age 54, as the Company's Chief Commercial Officer, effective as of August 11, 2025.

Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. Prior to joining the Company, Mr. Lialin had served as Chief Commercial Officer of DPBIO. From April 2025 to June 2025, he served as Vice President Business Development of Seonix Bio and from April 2022 to April 2024, he served as Vice President Sales & Consumer Success of ONI. From March 2020 to April 2022, Mr. Lialin served as Chief Commercial Officer of Invivoscribe, Inc. At the Company, he will lead go-to-market strategy, partnerships, and the expansion of the company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development.

In connection with his appointment, on July 25, 2025, Mr. Lialin and the Company entered into an offer letter (the "Offer Letter"). Pursuant to the Offer Letter, Mr. Lialin's initial annualized salary is $360,000 and he received a sign-on bonus of $10,000. Additionally, Mr. Lialin will be eligible to participate in the Company's bonus plan with a target incentive of up to 40% of his base salary. His salary and performance bonus percentage may be increased in the future at the discretion of the Compensation Committee of the Board. Mr. Lianlin's employment is on an "at-will" basis.

In connection with his appointment, and as provided in the Offer Letter, on August 11, 2025, the Company granted Mr. Lialin an option pursuant to its Amended & Restated 2022 Equity Incentive Plan to purchase 40,000 shares of the Company's common stock (the "Option"), which option will vest over four years, with 25% of the total number of shares subject to the Option vesting on August 11, 2026 and the balance vesting in 12 equal quarterly

installments thereafter, subject to Mr. Lialin's continued service to the Company on each applicable vesting date.

The foregoing description of the Offer Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Offer Letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

There are no transactions between Mr. Lialin and the Company that would be reportable under Item 404(a) of Regulation S-K. There also are no family relationships between Mr. Lialin and any director or executive officer of the Company. Mr. Lialin was not selected to serve as the Company's Chief Commercial Officer pursuant to any arrangement or understanding with any person. The Company has also entered into the Company's standard form Indemnity Agreement with Mr. Lialin.

## **Item 7.01 Regulation FD Disclosure.** 
On August 14, 2025, the Company issued a press release announcing that it has appointed Tony Lialin as its Chief Commercial Officer. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "1934 Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the 1934 Act, except as shall be expressly set forth by specific reference in such a filing.

## **Item 9.01 Financial Statements and Exhibits.** 
**(d) Exhibits.**

---

| | |
|:---|:---|
| Number | Description |
| 10.1 | [<u>Offer Letter, dated July 25, 2025, between VivoSim Labs, Inc. and Tony Lialin.</u>](vivs-ex10_1.htm)<br>|
| 99.1 | [<u>Press Release dated August 14, 2025.</u>](vivs-ex99_1.htm) |
| 104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). |

---

\* \* \*

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | VivoSim Labs, Inc. |
| Date: | August 14, 2025 | By:  | /s/ Keith Murphy |
|  |  |  | Name: Keith Murphy<br>Title: Executive Chairman |

---

------

## Exhibit 10.1

CONFIDENTIAL

**EXHIBT 10.1**

![img62398068_0.jpg](img62398068_0.jpg)

**VivoSim Labs, Inc.**

11555 Sorrento Valley Road, Suite 100

San Diego, CA 92121

July 25, 2025

Tony Lialin

[...\*\*\*...]

<u>RE: Offer Letter</u> 

Dear Tony:

On behalf of VivoSim Labs, Inc., and its subsidiaries, including, without limitation, namely Organovo Inc. and VivoSim, Inc. ("Company"), it is a great pleasure to extend you an offer of full-time employment as **Chief Commercial Officer,** contingent on approval of the Company's Board of Directors ("Board"), reporting to **Keith Murphy, Executive Chairman**. In making this offer, we are expressing our enthusiastic support for the skills and commitment you will bring to our exciting team. We are pleased to offer you the following:

**Salary:** Your base salary for this exempt position will be **$360,000** per year, paid bi-weekly and subject to deductions and income tax withholding as required by law or the policies of the Company. Future increases will be considered by the Compensation Committee in its review or executive compensation. You will be considered an **exempt** employee. Any future increases will be awarded on an annual basis based upon performance.

**Bonus:** You are eligible to participate in the Company's Bonus Plan, with a target incentive of up to **40%** of the portion of your annual base salary actually paid by Company; however, the actual bonus received will be based upon the Company's performance and the achievement of both corporate and individual goals each fiscal year. Bonus payments will be subject to required deductions and withholdings and are calculated as a proportion of annual W-2 earnings. The Company's Compensation Committee shall have the sole discretion to determine whether you have earned any bonus set forth in this paragraph, and if so, the amount of any such bonus.

At the Company, our salary merit increases, potential bonus amounts, and annual equity grants are based upon the assumption that an employee has provided services to the Company for the entire fiscal year. Therefore, if you join the Company at any time between April 1<sup>st</sup> and March 31<sup>st</sup> of any fiscal year, your potential salary merit increase, potential bonus, and equity grants, if any are awarded, will be

------

CONFIDENTIAL

prorated for the actual amount of service you provide during the fiscal year. If you join the Company in the fourth quarter of the Company's fiscal year (between Jan 1<sup>st</sup> and March 31<sup>st</sup>), you will not be eligible to participate in the annual performance review cycle for that fiscal year, and will not receive any salary increase, bonus, or equity increases in that fiscal year.

**Signing Bonus:** Should you accept the employment offer, the Company will offer you a signing bonus fee in the amount of **<u>$10,000.</u>** 

**Equity Package:** In addition, we are pleased to offer you **40,000 (forty thousand) stock option shares**, subject to approval by the Board's Compensation Committee. One-fourth (1/4<sup>th</sup>) of the shares will vest one year from the Vesting Commencement Date, which will be set by the Board when the shares are granted and the remainder on a quarterly basis thereafter over a period totaling four years from the Vesting Commencement Date, subject to your continuous service through such date, and subject to the terms and conditions of the Company's Amended & Restated 2022 Equity Incentive Plan.

**Benefits:** The Company provides eligibility for group medical, dental and vision insurance plans for employees and their dependents if you devote at least twenty (20) hours per week on average to the Company.

Should you be eligible for and accept the Company's offer, medical benefits become effective on the first of the month following date of hire. The Company also has a 401(k) retirement plan with a company specified match, and a Section 125 plan allowing employees to have a health care spending account and a dependent care spending account. These latter items allow employees to make contributions with pre-tax dollars. Finally, the Company also offers long term disability, accidental death & dismemberment and life insurance (at one times your annual base salary) fully paid for by the Company.

**Time Off:** Instead of providing a fixed number of vacation days in a given year, the Company permits employees the flexibility to take time off with pay for reasonable rest and relaxation at their discretion, subject to the Company's needs, the specific duties and expectations of each employee's position within the company, and receiving supervisor pre-approval. We also offer eight (8) paid holidays and Sick Leave Benefits.

Employees are eligible for sick leave beginning on the first day of employment and the Company provides up to 40 hours of paid sick leave annually, renewing January 1 each year.

**Start Date:** Should you find our offer attractive, we would like your official start date to be **<u>August 11, 2025</u>.**

This employment offer is contingent upon you signing our Employee Confidentiality Agreement providing legally required evidence of your right to work in the United States as well as the Company's successful completion of your references and background check. In consideration of your employment, you also agree to conform to the policies and standards of the Company.

Your employment will be "at-will" and either party may terminate the relationship at any time with or without cause and with or without notice.

------

CONFIDENTIAL

By your signature below, you acknowledge that you will be an exempt employee and this offer letter supersedes any prior Offer Letters provided to you by the Company, and represents the entire agreement between you and the Company, and that no verbal or written agreements, promises or representations that are not specifically stated in this offer, are or will be binding upon the Company. Any additions or modifications of these terms must be in writing and signed by you and the Company's Executive Chairman. On the first day of employment, you will be required to provide the Company with the legally required proof of your identity and authorization to work in the United States.

We hope that you'll accept this offer and look forward to welcoming you aboard! Please feel free to contact me if you have any questions.

---

| |
|:---|
| &nbsp;&nbsp;Sincerely, <br>/s/ Keith Murphy<br>|
| &nbsp;&nbsp;Keith Murphy<br>Executive Chairman |

---

------

CONFIDENTIAL

<u>To accept this job offer:</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Sign and date this job offer letter where indicated below.

Return a signed and dated document back within 3 days of the date of this letter. A copy of the document should be retained for your records. The document should be scanned and returned electronically to [...\*\*\*...].

**Accept Job Offer**<br>

By signing and dating this offer letter, I, Tony Lialin, accept this offer of employment from the Company.

Signature: <u>/s/ Tony Lialin</u> Date: <u>7/25/2025</u>

------

## Exhibit 99.1

**EXHIBIT 99.1**

**VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer**

*Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market*

San Diego, CA — August 14, 2025 — VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer.

<br>Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and the expansion of the Company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development.

Market Opportunity: According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024. Services represented 53.1% of revenue vs. models at 46.9% of revenue. The United States accounted for $325M (50.8%) of the global market for liver toxicology models and services. Adoption of 3D human-relevant systems is rising, with the global in vitro liver model market growing at 5.9% CAGR from 2020 to 2024.

**Category Tailwinds:** Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs). Regulatory momentum, including the FDA Modernization Act 2.0 (2022), supports validated alternatives and is catalyzing broader adoption of human-relevant in vitro models for ADME and toxicology.

**How AI Helps:** VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays. By improving signal-to-noise in dose-response analyses, the platform helps project teams prioritize candidates and plan studies with greater confidence.

"VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier," said Tony Lialin, Chief Commercial Officer, VivoSim Labs. "We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises."

"Tony has a rare track record of turning disruptive science into durable commercial engines," said Keith Murphy, Executive Chairman, VivoSim Labs. "As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a

------

protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need."

**About VivoSim Labs**

VivoSim Labs, Inc. ("VivoSim" and the "Company"), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ("FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.

**Forward-Looking Statements**

*Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding expansion of the Company's San Diego-based services; the potential for the Company's organ-specific 3D models and AI-driven analytics to deliver decision-ready insights earlier in development; the market opportunity and market size of gastrointestinal in-vitro models and toxicology services; and the ability of the Company's services to improve signal-to-noise in dose-response calls or help project teams prioritize candidates and studies with greater confidence. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.* 

**Contact**

Investor Relations

<u>info@vivosim.ai</u><br>VivoSim Labs, Inc.

------